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Abstract Families bearing mutations in the presenilin-1 (PS1)
gene develop Alzheimer’s disease (AD). However, the mechanism
through which PS1 causes AD is unclear. The co-immunoprecip-
itation with PS1 in transfected COS-7 cells indicates that PS1
directly interacts with endogenous L-catenin, and the interaction
requires residues 322^450 of PS1 and 445^676 of L-catenin.
Both proteins are co-localized in the endoplasmic reticulum.
Over-expression of PS1 reduces the level of cytoplasmic L-
catenin, and inhibits L-catenin-T cell factor-regulated transcrip-
tion. These results indicate that PS1 plays a role as inhibitor of
the L-catenin signal, which may be connected with the AD
dysfunction.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Presenilin-1 (PS1) has been cloned as the causal gene in
chromosome 14 of familial Alzheimer’s disease [1]. Mutations
on PS1 cause an early onset form of AD with an autosomal
dominant inheritance pattern. Genetic studies show that mu-
tations of PS1 exhibit 100% penetrance in causing AD [2,3].
While the mechanism connecting PS1 with AD is unclear,
mutations in presenilins a¡ect amyloid L protein (AL) proc-
essing. Recent studies indicate that cell lines, transgenic mice
or patients expressing mutant forms of PS1 show a selective
increase in production of AL1ÿ42 [4^7]. Mutations in the pre-
senilins also activate apoptotic pathways and render neurons
more vulnerable to stressors, such as AL neurotoxicity [8^12].
However, the underlying mechanism is still unclear. We re-
cently established that PS1 is associated in vitro and in vivo
with GSK-3L and its substrate tau [13]. This suggests that PS1
may act as a molecular tether, connecting GSK-3L with im-
portant substrates, much like the kinase binding proteins
AKAP and RACK1 modulate activity by controlling the as-
sociation of protein kinases A and C with their substrates
[14,15].
The level of cytosolic L-catenin, which is a component of
the Wnt/Wingless signalling pathway, is regulated by GSK-3L,
and L-catenin is a substrate for GSK-3L. This makes the con-
nection between PS1 and L-catenin of particular interest.
2. Materials and methods
2.1. cDNA construct
PS1 mutants (N250, N298, D290^319 and D322^450 and the point
mutations) were produced by PCR-based, site-directed mutagenesis
using wild type PS1 lacking the VRSQ motif as a template. After
subcloning the products into the pCIneo vector (Promega), the se-
quences were con¢rmed by sequencing the entire region.
2.2. Antibodies
Polyclonal antibodies N1-12 and hL312 were raised in rabbits
against the N-terminal region, amino acid residues 1^12 and the hy-
drophilic loop domains, amino acids 312^343 of human PS1. The
extracted antisera were a⁄nity puri¢ed with corresponding peptide-
coupled agarose gel columns (Pierce), and the antibodies used for
experiments. The monoclonal antibody for L-catenin was obtained
from Transduction Lab (Kentucky).
2.3. Transient transfection
COS-7 cells were cultured in DMEM/10% FBS. For transient ex-
pression, 5U105 cells were plated on 10 cm2 dishes and grown over-
night. Each cDNA (2 Wg/ml) was transfected into COS-7 cells using
Lipofectamine (4 Wl/ml; Gibco BRL), and the cells were harvested
after 48 h in TBS (10 mM Tris-HCl (pH 7.4), 150 mM NaCl/1%
Triton X-100). The lysates were then centrifuged at 15 000 rpm at
4‡C. The supernatant was collected and used for immunoprecipita-
tion. For dividing into cytoplasmic and membrane fractions, the cells
were homogenized in TBS by te£on homogenizer. The homogenates
were then centrifuged at 15 000 rpm at 4‡C for 30 min, and the super-
natant was used as the cytoplasmic fraction. The resulting pellet was
lysed in TBS/1% Triton X-100 and the lysate was centrifuged. The
supernatant was then used as the membrane fraction.
2.4. Immunoprecipitation
The cell extracts from each transfection were preincubated with
protein G Sepharose (Pharmacia) and then incubated with the indi-
cated antibodies at 4‡C overnight. The immunocomplexes were pre-
cipitated by incubation with protein G Sepharose at room temper-
ature for 2 h, washed 5 times in TBS/1% Triton X-100 and eluted with
0.1 M glycine (pH 2.5). For detection of L-catenin, the immunopre-
cipitates were eluted by incubation with Laemmli sample bu¡er at
95‡C for 3 min.
2.5. Stable cell line
Each PS1 construct was transfected into human neuroblastoma SH-
SY-5Y cells by Lipofectamine (Gibco). The PS1 expressing cells were
selected by culture in normal growth medium containing G418. The
established cell lines were maintained in normal growth medium with-
in 10 passages and used for experiment.
2.6. Immunocytochemistry
SH-SY cells plated on poly-L-lysine coated slide glasses (Lab Tech)
were ¢xed with 4% paraformaldehyde. The plasma membrane was
permeabilized with Tris-bu¡ered saline containing 0.2% Triton X-
100 for 5 min. Double immunostaining was performed using anti-
PS1 (hL312, 1:500) and anti-L-catenin (1:500) as primary antibodies,
and FITC-conjugated rabbit anti-mouse IgG (1:1000) and Cy3-con-
jugated goat anti-rabbit IgG as secondary antibodies. Dual immuno-
£uorescence images were captured simultaneously using a confocal
laser scanning microscope (CLSM, Bio-Rad MRC 1024). Using Voxel
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VIew (Vital Image) software on a workstation (SGI, O2), serial opti-
cal section images were reconstructed into 3-dimensional (3D) images,
where voxel numbers represent relative amounts of di¡erent proteins.
2.7. L-Catenin-Tcf-regulated transcription assay
cDNA (2 Wg) consisting of 1 Wg of hTcf-4-luciferase reporter gene
[16] and 1 Wg of each PS1 construct or vector was transfected into
PC12 cells using Lipofectamine (BRL). After 48 h, cells were lysed in
luciferase extraction bu¡er (40 mM tricine (pH 7.8), 50 mM NaCl,
2 mM EDTA, 1 mM MgSO4, 5 mM DTT, and 1% Triton X-100),
and 20 Wl of lysate was assayed for luciferase by mixing with assay
bu¡er containing 40 mM tricine (pH 7.8), 10 mM MgSO4, 500 WM
EDTA, 10 mM DTT, 500 WM coenzyme A, and 500 WM ¢re£y luci-
ferin. Samples were analyzed on a Turner Designs Luminometer.
3. Results
3.1. Co-localization of PS1 and L-catenin in neuroblastoma
cell line SH-SY-5Y cells
To examine the connection between PS1 and L-catenin, we
¢rst investigated the localization of both proteins in SH-SY-
5Y cells stably overexpressing wild type PS1. Using anti-PS1
and anti-L-catenin antibodies, intracellular 3D co-localization
of PS1 and L-catenin was investigated by imaging the two
immunostained proteins within a cell. Fig. 1A,B shows the
3D localization of PS1 and L-catenin in SH-SY-5Y cells re-
spectively. As previously indicated [17,18] PS1 is localized in
the endoplasmic reticulum (ER)/Golgi apparatus. L-Catenin
was detected in peripheral and interior cytoplasm. Co-local-
ization of PS1 and L-catenin was observed in the ER and the
proximity of the plasma membrane (Fig. 1C,D). PS1 shared
4.2U105 voxels (Fig. 1A), and L-catenin 5.1U105 voxels (Fig.
1B). The co-localized area of PS1 and L-catenin was 1.0U105
voxels (Fig. 1D). These features of localization were similar in
mutant PS1 expressing cells (data not shown).
3.2. Interaction between PS1 and L-catenin in transiently
transfected COS-7 cells
To investigate the association of PS1 with L-catenin, we
transfected wild type PS1 into COS-7 cells, and examined
the distribution of each protein in cell homogenate by classi-
fying the protein populations into cytoplasmic and membrane
fractions. In the membrane fraction, the 48 kDa PS1 full
length form and the 19 kDa PS1 C-terminal fragment were
observed using hL312 (Fig. 2A, lanes 3 and 4), recognizing
PS1 residues between 312 and 330. However, no PS1 was
observed in the cytoplasmic fraction (Fig. 2A, lanes 1 and
2). PS1 transfection showed an increased level of full length
PS1 in the membrane fraction (Fig. 2A, lane 4), which might
indicate a lower activity of proteolytic cleavage of full length
PS1 in this cell type. Anti-L-catenin antibody indicated the
presence of endogenous L-catenin in both cytoplasm and
membrane fractions (Fig. 2B, lanes 1^4). We then investigated
whether these proteins were associated with each other during
immunoprecipitation. L-Catenin was immunoprecipitated us-
ing the anti-L-catenin antibody and the subsequent immuno-
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Fig. 1. 3D co-localization of PS1 and L-catenin in the SH-SY-5Y cell. A: PS1, visualized following immunostaining with anti-PS1 and imaging,
predominantly localized in endoplasmic reticulum and Golgi apparatus. The PS1 localizing area was 4.2U105 voxels as estimated by 3D recon-
struction software. B: L-Catenin, visualized following immunostaining with anti-L-catenin and imaging, predominantly localized in peripheral
and interior cytoplasm. The localizing area was 5.1U105 voxels as estimated by 3D reconstruction software. C: The PS1 image (red) and L-cat-
enin image (green) were merged depicting the co-localizing image (yellow). D: The co-localized area between PS1 and L-catenin was image-
processed and estimated to be 1.0U105 voxels.
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blots were probed using the anti-PS1 antibody, hL312 (Fig.
2A, lanes 5^8). The results indicate the precipitation of 48
kDa full length PS1 in the membrane fraction (Fig. 2A, lanes
7 and 8), but not in the cytoplasmic fraction (Fig. 2A, lanes 5
and 6). Conversely, PS1 was immunoprecipitated using
hL312, and then probed by anti-L-catenin antibody (Fig.
2B, lanes 5 and 6). L-Catenin was co-immunoprecipitated
with PS1 in the membrane fraction. These results suggest
that PS1 and L-catenin are together in the membrane fraction
and associate with each other.
3.3. Determination of binding site in PS1 and L-catenin
To determine the binding site in each protein, we generated
a number of PS1 and L-catenin cDNA constructs containing
varying deletions (Fig. 3A,C). D322^450, N298 and N250 are
PS1 constructs that have the C-terminus deleted (Fig. 3A).
The D290^319 construct contains a deletion corresponding
to exon 9 of the PS1 gene (Fig. 3A). COS-7 cells were trans-
fected with each PS1 construct. The endogenous L-catenin was
then immunoprecipitated using the anti-L-catenin antibody,
and the subsequent immunoblots were probed using the
anti-PS1 antibody, N1-12. Wild type and D290^319 PS1 co-
immunoprecipitated with endogenous L-catenin, but D322^
450, N298 and N250, with C-terminal deletions, did not.
The result indicates that residues 322^450 are necessary for
the association of PS1 with L-catenin. Conversely, we pro-
duced three L-catenin cDNA constructs containing varying
deletions (Fig. 3C). D1^436 is a L-catenin construct in which
the ¢rst half of L-catenin has been removed. D445^676 is a
cDNA construct in which the second half of the repeat has
been removed. The wild type PS1 and each of the L-catenin
constructs were co-transfected into COS-7 cells. PS1 was then
immunoprecipitated using PS1 antibody hL312, and the sub-
sequent immunoblots were probed with the anti-L-catenin
antibody. The full length and D1^436 L-catenin co-immuno-
precipitated with wild type PS1, but D445^676 did not (Fig.
3D). This ¢nding indicates that the latter half of the repeat in
L-catenin (amino acid residues 445^676) is required for the
binding of PS1. This suggests that PS1 residues 322^450 are
associated directly with L-catenin region 445^676.
3.4. The e¡ects of PS1 on the L-catenin signal
Membrane-associated L-catenin is involved in cell adhesion
and its soluble form in Tcf-regulated transcription. The levels
of membrane-associated L-catenin were not a¡ected by the
expression of PS1 (data not shown). To better understand
the physiology of the PS1/L-catenin connection, we investi-
gated the e¡ects of PS1 on L-catenin-Tcf-regulated transcrip-
tion (CRT) in cells transiently expressing PS1 (Fig. 4A). Wild
type PS1 transfection signi¢cantly reduced CRT activity by
approximately 20% of vector control. In the case of the mu-
tant form of PS1 expression, CRT activity was almost 10% of
vector control. Since CRT is regulated by the level of cyto-
plasmic L-catenin, we investigated the level of cytoplasmic
L-catenin after transient transfection of each PS1 in COS-7
cells. The wild type and mutant forms of PS1 expression sig-
ni¢cantly reduced the level of cytoplasmic L-catenin (Fig. 4B,
left panel) without a¡ecting the level of membrane-bound
L-catenin (data not shown). This inhibition of cytoplasmic
L-catenin by PS1 expression was restored by LiCl treatment
(Fig. 4B, right panel), known as an inhibitor of GSK-3L. Our
¢ndings suggest that the PS1, GSK-3L, and L-catenin complex
inhibits the L-catenin signalling cascade.
4. Discussion
PS1 is known as a causative gene for chromosome 14-linked
familial Alzheimer’s disease [1], and overexpression of PS1
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Fig. 2. PS1 associates with L-catenin in COS-7 cells. pCIneo vector and wild human PS1 cDNA construct were transfected into COS-7 cells.
Cells were homogenized and separated into cytoplasmic and membrane fractions as described in Section 2. A: PS1 in each lysate (left panel)
and immunocomplex using anti-L-catenin antibody (right panel) were probed by anti-PS1 antibody (hL312). PS1 transfection showed the full
length form and it co-immunoprecipitated with endogenous L-catenin in the membrane fraction. Cytoplasmic fraction, lanes 1, 2, 5 and 6;
membrane fraction, lanes 3, 4, 7 and 8; pCIneo transfection, lanes 1, 3, 5 and 7; wild human PS1 transfection, lane 2, 4, 6 and 8. B: Con-
versely, L-catenin in each lysate (left panel) and immunocomplex by anti-PS1 antibody (hL312) were probed by anti-L-catenin antibody (right
panel). L-Catenin could be detected in both cytoplasmic and membrane fractions, but L-catenin in soluble fraction could not form an immuno-
complex with PS1. Cytoplasmic fraction, lanes 1 and 2; membrane fraction, lanes 3, 4, 5 and 6; pCIneo transfection, lanes 1, 3 and 5; wild hu-
man PS1 transfection, lanes 2, 4 and 6.
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mutant enhances AL42 secretion in conditioned medium [4^7].
With regard to physiological function, the PS1 null mutant
mouse shows loss of normal neurogenesis and axial formation
[19,20]. Genetic studies of Caenorhabditis elegans suggest that
PS1 may be functionally connected with the Notch signalling
pathway [21]. Our ¢nding was that PS1 directly binds to
L-catenin, and inhibits CRT, which plays an essential role in
the Wnt/Wingless signalling pathway [22,23]. The Wingless/
Wnt signal interacts with the Notch signal through disheveled
(Dsh), suggesting that PS1 may play a role in the signalling
pathway of Dsh, which is related to GSK-3L [24], and L-cat-
enin [25]. LiCl treatment restores the inhibitory e¡ect of PS1
on cytoplasmic L-catenin, thus indicating that GSK-3L may
account for the inhibitory e¡ect of PS1 on cytoplasmic L-cat-
enin levels. Recently we established what we believe is a direct
link between PS1 and GSK-3L. PS1 binds to GSK-3L and its
substrate L-catenin, possibly enhancing the phosphorylation
of L-catenin, leading to the degradation of L-catenin by the
ubiquitin-proteasome cascade [26]. The binding of L-catenin
with wild type and mutant PS1 did not show any signi¢cant
di¡erence (data not shown), but the mutant form of PS1 in-
hibits CRT more than the wild type. The reason is that mu-
tant PS1 associates more than wild-type with GSK-3L thus
increasing kinase activity [13].
Amino acid residues 322^450 of PS1 were required for bind-
ing to L-catenin, a region similar to the N-catenin binding site
[27]. GSK-3L associated with PS1 amino acid residues 250^
298. In physiological conditions, PS1 is cleaved between 290
and 298, and mainly exists as 28 kDa N- and 19 kDa C-ter-
minal fragments. GSK-3L associates with a region of the N-
terminal fragment [13], and L-catenin binds to a region of the
C-terminal fragment. Full length PS1 may be required for the
interaction of GSK-3L with L-catenin. Some mutant forms of
PS1 are resistant to endoproteolytic cleavage [28,29]. However,
the possibility cannot be ruled out that the heterodimer of PS1
fragments may induce the interaction of the two proteins.
L-Catenin is known to associate with partner proteins APC
[30] or axin [16,31] to regulate its cytoplasm level. The L-
catenin signal may be tightly regulated by these partner pro-
teins in response to extracellular stimuli. PS1 is a member of
these partner proteins, and is involved in the regulation of the
L-catenin signal as well as other partner proteins. Since PS1 is
connected with Alzheimer’s disease, the L-catenin signal may
be connected with the onset of Alzheimer’s disease. Alterna-
tively, PS1 may interact with other proteins, and induce neu-
ronal death with formation of amyloid plaques and neuro¢-
brillary tangles.
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Fig. 3. Analysis of PS1 and L-catenin binding. A: Schematic drawing of PS1 deletion mutants. Wild type PS1 consists of 467 animo acids
(wild). The N250 and N298 deletion constructs have the C-terminus of PS1 deleted beyond residues 250 and 298 respectively. The D322^450
and D290^319 constructs contain deletions between residues 322^450 and 290^319, respectively. B: These mutant PS1 constructs were transi-
ently transfected into COS-7 cells. The expression of each PS1 was analyzed using 1/10 volume of total cell lysate (left panel). The rest of each
cell lysate was used for immunoprecipitation by the anti-L-catenin antibody, and analyzed for formation of immunocomplexes of L-catenin
with PS1 deletant mutants (right panel). Wild and D290^319 co-precipitated with L-catenin, while N250, N298, and D322^450 did not. C:
Schematic drawing of L-catenin deletion mutants, lacking residues 1^436 (D1^436) and 445^676 (D445^676) respectively. D: These di¡erent
forms of L-catenin and human wild type PS1 were co-transfected in COS-7 cells. The expression of each L-catenin was analyzed using 1/10 vol-
ume of total cell lysate (left panel). The rest of each cell lysate was used for immunoprecipitation by the anti-PS1 antibody (hL312), and ana-
lyzed for the formation of immunocomplexes of PS1 with L-catenin deletion mutants (right panel). D1^436 was recovered in the immunocom-
plexes with PS1, while D445^676 was not recovered.
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Fig. 4. E¡ects of PS1 on L-catenin signal. A: L-Catenin-Tcf-regu-
lated transcription (CRT) in transfection assay. Each PS1 construct
and pTOPFLASH reporter contained an optimized Tcf-binding site
5P of a luciferase reporter gene co-transfected into PC12 cells. CRT
reporter activity was determined as the luciferase activity by Lumin-
ometer, and is expressed as mean þ S.D. (n = 3). B: Each PS1 con-
struct was transfected into COS-7 cells and L-catenin in cytoplasmic
fractions was examined with and without LiCl (30 mM) treatment.
The cytoplasmic L-catenin was reduced by PS1 expression, and re-
stored by LiCl treatment.
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